Xylem's third quarter showed a growing gap between what customers are ordering and what the company can turn into revenue. Adjusted EPS of $1.44 missed the $1.47 consensus and the $1.50 Earnings Whisper number by 4.0%. Revenue of $2.201 billion fell 3.0% year over year and missed consensus by 3.5%. Organic revenue was flat, well short of the roughly 3% growth management had guided on the second-quarter call. Earnings still grew 5.1%. Orders, meanwhile, rose 10% organically and backlog reached a record $5.5 billion, up 13%. That is the central tension: demand signals are building, but revenue conversion is slipping, and management responded by cutting the full-year outlook.

The quality of the earnings growth deserves scrutiny. Adjusted net income was $336 million, essentially flat with $333 million a year ago. The 5.1% EPS gain came almost entirely from a share count that fell to 233.0 million diluted shares from 244.1 million. That reduction was funded by $1.58 billion of repurchases this year. GAAP EPS of $1.25 rose 34%, but that figure was flattered by a much smaller loss on business sales ($5 million versus $37 million) and lower restructuring costs. The genuine operating positive was margin. Adjusted EBITDA margin expanded 70 basis points to 23.9%, with gross profit up despite lower sales, as productivity and pricing outran inflation, weaker volumes and mix. The balance sheet tells a less comfortable story:

• Cash fell to $708 million from $1.48 billion.
• Long-term debt rose to $2.37 billion from $1.41 billion.
• Quarterly interest expense more than tripled to $21 million.

The guidance reset is where the quarter really landed:

• Full-year organic revenue growth was cut to roughly flat, from 2% to 3% previously and 2% to 4% at the start of the year.
• Reported revenue guidance fell to about $8.95 billion, down 1% year over year.
• Adjusted EPS guidance dropped to $5.40 to $5.45 from $5.55 to $5.70. That erases the second-quarter raise and lands near the original midpoint.
• Free cash flow margin was pinned at about 10.2%, the bottom of the prior range.

More telling, the fourth quarter is now expected to decline 1% to 2% organically. Last quarter, management talked about a mid-single-digit exit rate. The tone shifted accordingly, from enthusiasm about a strong 2027 to a "mixed operating environment" and more cautious commentary on municipal customers.

The segment detail explains the disconnect. Measurement and Control Solutions orders jumped 30% organically on large water and gas metering awards. However, those deployments run into the second half of 2027 and 2028. Segment revenue fell 5% organically, and management expects a further sequential step down in the fourth quarter that persists into the first half of 2027. Utility affordability pressures, flagged in electric metering last quarter, have now spread into water metering, with softness in short-cycle book-and-ship business. Water Solutions and Services revenue slipped 2%, treatment projects are slipping 4 to 8 months, and its fourth-quarter growth outlook was cut to low single digits from high single digits. The bright spot is Applied Water: organic revenue rose 9% and orders rose 15%. Data center orders were up more than 200% after rising more than 300% in the prior quarter, and management highlighted a new ultra-pure water win at a U.S. semiconductor fab and an expanded Amazon relationship.

Management is clearly trying to steer the story toward portfolio quality. It plans to divest Applied Water International and Specialty Flow Control, which together represent about 9% of revenue and less than 5% of EBITDA. The sale would be margin-accretive and cut China exposure roughly in half, to about 1%. A three-segment structure begins in 2027, and the Cornell Roper acquisition is expected to close this quarter. These are credible long-term moves. They arrive, however, alongside a CFO transition, leverage heading toward 1.5x to 2x, and fourth-quarter margin guidance of about 24.5% that leans heavily on execution while volumes contract. Bears have legitimate ammunition here, even though the margin and order data keep the growth narrative intact.

The market had already priced in some of this disappointment. Shares entered the report at $108.24, down 11.6% from the open following the July report. That July session also marked the inter-earnings high of $127.16. The stock is 8.6% below its 200-day moving average. It set a 52-week low of $98.58 on October 1 and has since recovered about 10% off that level. Investor sentiment improved modestly, from slightly negative to slightly positive, which reflects tentative rather than enthusiastic positioning. The price and AVWAP trend readings remain negative, consistent with a stock that has been sold on rallies since summer.

The bottom line is that Xylem delivered margin discipline and record backlog but missed on both lines and walked back its full-year growth story. Earnings growth was carried largely by a shrinking share count rather than operating income. Investors now have to trust that metering and treatment orders convert in 2027, while affordability pressures, project delays and higher leverage argue for patience over conviction.